Suppr超能文献

[酮内酯类和恶唑烷酮类。作用机制及抗菌谱]

[Ketolides and oxazolidinones. Mechanisms of action and antibacterial spectrum].

作者信息

Muller-Serieys C

机构信息

Service de Microbiologie, Groupe Hospitalier Bichat-Claude Bernard, 46, rue Henri-Huchard, F 73877 Paris.

出版信息

Presse Med. 2000 Dec 2;29(37):2061-4.

Abstract

CHANGING RESISTANCE OF GRAM-POSITIVE COCCI: Several new families of antibiotics are under development in response to the changing resistance of Gram-positive cocci. Linezolide, the leading member of the oxazolidinone family and telithromycin and ABT-773, leading members of the ketolide family have reached an advanced stage of development. INHIBITION OF PROTEIN SYNTHESIS: Oxazolidinones and ketolides inhibit protein synthesis at different levels. Oxazolidinones inhibit formation of the 70S initiation complex and ketolides block the protein elongation step by inhibiting peptidyl transferase. MECHANISMS OF RESISTANCE: To date, no cross resistance of linezolide with other antibiotic families used for the treatment of Gram-positive bacteria has been observed. It is quite difficult to obtain resistant mutants in the laboratory but two point mutations on the 23S ribosome fraction have been described in vivo. Resistance of Gram-positive cocci to macrolides occur via mechanisms altering the target (methylation of 23S rRNA or ribosome protein mutations) or via mechanisms involving active efflux. LINEZOLIDE: Linezolide is highly active in vitro against meticillin-resistant Staphylococcus aureus (MRSA), against Streptococcus including resistant pneumococcal strains, and against glycopeptide-resistant E. faecium and E. faecalis strains. TELITHROMYCIN AND ABT-773: These ketolides are active against Streptococcus and Pneumococcus strains exhibiting erythromycin-inducible resistance and resistance by active efflux. In addition, these antibiotics are highly active against other bacteria causing respiratory tract infections (Moraxella and Haemophilus), anaerobic germs and intracellular germs (Legionella).

摘要

革兰氏阳性球菌耐药性的变化

针对革兰氏阳性球菌不断变化的耐药性,有几种新型抗生素家族正在研发中。恶唑烷酮类的主要成员利奈唑胺以及酮内酯类的主要成员泰利霉素和ABT - 773已进入研发后期。

蛋白质合成的抑制

恶唑烷酮类和酮内酯类在不同水平上抑制蛋白质合成。恶唑烷酮类抑制70S起始复合物的形成,而酮内酯类通过抑制肽基转移酶来阻断蛋白质延伸步骤。

耐药机制

迄今为止,尚未观察到利奈唑胺与用于治疗革兰氏阳性菌的其他抗生素家族之间存在交叉耐药性。在实验室中很难获得耐药突变体,但在体内已描述了23S核糖体片段上的两个点突变。革兰氏阳性球菌对大环内酯类的耐药性通过改变靶点的机制(23S rRNA甲基化或核糖体蛋白突变)或通过涉及主动外排的机制产生。

利奈唑胺

利奈唑胺在体外对耐甲氧西林金黄色葡萄球菌(MRSA)、包括耐药肺炎球菌菌株的链球菌以及对糖肽类耐药的屎肠球菌和粪肠球菌菌株具有高度活性。

泰利霉素和ABT - 773:这些酮内酯类对表现出红霉素诱导性耐药和主动外排耐药的链球菌和肺炎球菌菌株具有活性。此外,这些抗生素对引起呼吸道感染的其他细菌(莫拉克斯氏菌和嗜血杆菌)、厌氧菌和细胞内细菌(军团菌)具有高度活性。

相似文献

2
Clinical efficacy of ketolides in the treatment of respiratory tract infections.
J Antimicrob Chemother. 2004 Jun;53(6):918-27. doi: 10.1093/jac/dkh169. Epub 2004 Apr 29.
3
The ketolides: a critical review.
Drugs. 2002;62(12):1771-804. doi: 10.2165/00003495-200262120-00006.
6
[Macrolides, ketolides and streptogramins].
Enferm Infecc Microbiol Clin. 2003 Apr;21(4):200-7; quiz 208, 219.
9
Ketolides in the treatment of respiratory infections.
Expert Opin Pharmacother. 2002 Mar;3(3):277-97. doi: 10.1517/14656566.3.3.277.
10
Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
Expert Opin Emerg Drugs. 2003 Nov;8(2):297-321. doi: 10.1517/14728214.8.2.297.

引用本文的文献

1
ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.
Antimicrob Agents Chemother. 2003 Mar;47(3):1129-31. doi: 10.1128/AAC.47.3.1129-1131.2003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验